Mylan Agrees to Pay $465 million in a Settlement for EpiPen Overcharges

Mylan, the makers of EpiPen, and federal investigators finalized a $465 million settlement of charge the drugmaker avoided paying state Medicaid programs higher rebates by improperly classifying the brand name drug as a generic medication. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.